glp-1 podcast We’re LIVE

Updates in Medicine | SGLT2 Inhibitors What the Guidelines Say (20232024): HF (HFrEF & HFpEF): AHA/ESC Class I CKD: KDIGO First-line with... | Instagram

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) are no longer viewed solely as diabetes drugs. They have received a Class I recommendation for the treatment of which specific cardiovascular condition, even in patients WITHOUT

GLP-1 medications are a powerful tool for weight loss but they're not the whole picture. When your appetite drops significantly, it's easy to eat less without eating right. And that's

Eden GLP-1 Review 2026: Fast Approval and Fair Pricing - Nutrition and Nourishment Collective

It's a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging